目的 探究更年寧心顆粒聯(lián)合希明婷治療女性更年期綜合征的臨床療效。方法 選取2015年3月-2015年12月在大連市西崗區(qū)婦幼保健計劃生育服務(wù)中心接受治療的更年期綜合征患者156例，隨機分成對照組和治療組，每組各78例。對照組患者口服希明婷片，1片/次，3次/d。治療組在對照組的基礎(chǔ)上口服更年寧心顆粒，1包/次，2次/d。兩組患者連續(xù)治療4個月。觀察兩組患者的臨床療效，比較兩組治療前后的漢密爾頓抑郁量表（HAMD）、Kupperma和更年期生活質(zhì)量（MRS）評分，以及雌二醇（E₂）、促卵泡激素（FSH）和黃體生成素（LH）水平，同時觀察兩組患者不良反應(yīng)情況。結(jié)果 治療后，對照組和治療組的總有效率分別為87.2%和96.2%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，治療組HAMD、Kupperma和MRS評分均低于對照組，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，治療組E₂水平高于對照組，且FSH和LH水平低于對照組，但兩組比較差異無統(tǒng)計學意義。治療過程中對照組和治療組的不良反應(yīng)發(fā)生率分別為15.4%和11.5%，兩組不良反應(yīng)發(fā)生率比較差異有統(tǒng)計學意義（P<0.05）。結(jié)論 采用更年寧心顆粒聯(lián)合希明婷治療女性更年期綜合征，可改善患者生活質(zhì)量、調(diào)節(jié)患者體內(nèi)的激素水平，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the clinical effect of Gengnian Ningxin Granules combined with Ximingting Tablets in treatment of menopausal syndrome. Methods Patients (156 cases) with menopausal syndrome in Women Health Care, Maternal and Child Health Care Family Planning Service Center of Xigang District of Dalian from March 2015 to December 2015 were randomly divided into control and treatment groups, and each group had 78 cases. Patients in the control group were po administered with Ximingting Tablets, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Gengnian Ningxin Granules on the basis of the control group, 1 bag/time, twice daily. Patients in two groups were treated for 4 months. After treatment, the efficacy was evaluated, and the scores of HAMD, Kupperma, and MRS, and the levels of E₂, FSH, and LH in two groups were compared, at the same time, adverse reaction in two groups were observed. Results After treatment, the clinical efficacy in the control and treatment groups were 87.2% and 96.2%, respectively, and there were differences between two groups (P<0.05). After treatment, the scores of HAMD, Kupperma, and MRS in treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, E₂ level in the treatment group was higher than that in the control group, FSH and LH levels were lower than those in the control group, however, there were no differences between two groups. During the treatment, adverse reaction rate in the control and treatment groups were 15.4% and 11.5%, respectively, and there were differences between two groups (P<0.05). Conclusion Gengnian Ningxin Granules combined with Ximingting Tablets has a significant clinical effect in treatment of menopausal syndrome, and can improve the quality of life, and regulate the hormone levels, which has a certain clinical application value.